AFFiRiS AG
AFFiRiS AG's Overview
AFFiRiS AG is an Austrian clinical-stage biotechnology company focused on developing novel peptide-based immunotherapies for chronic neurodegenerative and cardiometabolic diseases. Utilizing its proprietary AFFITOME® technology platform, the company aims to create treatments that stimulate the body's own immune system to combat misfolded proteins, which are hallmarks of conditions such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy (MSA). Their approach targets specific epitopes to ensure high specificity and safety, with several candidates having progressed into clinical trials. AFFiRiS is dedicated to addressing significant unmet medical needs and improving the lives of patients suffering from these debilitating conditions.
Where is AFFiRiS AG's Headquarters?
HQ Function
The headquarters serves as the central hub for AFFiRiS AG's research and development, clinical operations, strategic partnerships, and corporate administration.
Notable Features:
Located within the Vienna BioCenter, a leading life sciences hub in Europe, providing access to state-of-the-art infrastructure, core facilities, and a vibrant scientific community.
Work Culture:
The work culture at AFFiRiS AG is likely highly collaborative, innovative, and science-driven, with a strong focus on R&D excellence and achieving breakthroughs in immunotherapy for complex diseases.
HQ Significance:
The Vienna BioCenter location offers strategic advantages, including proximity to academic research, potential collaborators, and a skilled talent pool, fostering innovation and growth.
Values Reflected in HQ: The headquarters' location and function reflect AFFiRiS's commitment to cutting-edge science, innovation, collaboration, and its mission to tackle challenging diseases.
Location:
While AFFiRiS AG's primary operations and headquarters are in Vienna, Austria, its global presence is established through international clinical trials conducted across multiple countries in Europe and North America. The company also engages in global collaborations with research institutions and pharmaceutical partners to advance its therapeutic pipeline. Its target patient populations for diseases like Alzheimer's and Parkinson's are worldwide, reflecting a global outlook for its potential therapies.
Street Address:
Karl-Farkas-Gasse 22, Campus Vienna BioCenter 3
City:
Vienna
State/Province:
Vienna
Country:
Austria
AFFiRiS AG's Global Presence
Buying Intent Signals for AFFiRiS AG
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of AFFiRiS AG
As of April 2025, AFFiRiS AG' leadership includes:
Investors of AFFiRiS AG
AFFiRiS AG has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Based on publicly available information, there have been no major executive hires or exits announced by AFFiRiS AG in the last 12-18 months, suggesting stability in the core leadership team. Any changes would typically be communicated via press releases on their official website.
Technology (Tech Stack) used by AFFiRiS AG
Discover the tools AFFiRiS AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AFFiRiS AG Email Formats and Examples
AFFiRiS AG likely uses common corporate email formats. Based on patterns observed in similar European biotech companies, the most probable format is [first].[last]@affiris.com or [first_initial][last_name]@affiris.com.
[first].[last]@affiris.com
Format
oliver.siegel@affiris.com
Example
80%
Success rate
News and media
AFFiRiS AG Press Release • 2023-06-20
AFFiRiS AG Announces First Patient Enrolled in Phase 1 Clinical Trial of its ATTR Amyloidosis Immunotherapy Candidate ACS-001
AFFiRiS AG announced the enrollment of the first patient in its Phase 1 clinical trial for ACS-001, an active immunotherapy candidate targeting ATTR amyloidosis, a rare, progressive, and fatal disease. The trial will assess safety, tolerability, and immunogenicity....more
European Pharmaceutical Review • 2022-10-18
AFFiRiS receives US patent for Parkinson’s disease treatment
AFFiRiS AG has been granted a new US patent for its lead candidate, AFFITOPE® PD01, an active immunotherapy for the treatment of Parkinson’s disease. The patent covers the medical use of PD01 for treating or preventing synucleinopathies....more
AFFiRiS AG Press Release • 2021-09-16
AFFiRiS AG reports positive long-term data from Phase I studies with AFFITOPE® PD01A in patients with early Parkinson’s disease
AFFiRiS AG reported encouraging long-term follow-up data from Phase I studies of AFFITOPE® PD01A in early Parkinson's disease patients, showing sustained antibody response and favorable safety profile. These results support further development of their alpha-synuclein targeting immunotherapy....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including AFFiRiS AG, are just a search away.